<table border="0" cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3: Clinically Significant Drug Interactions with Celecoxib</caption>
<tbody>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">  Drugs</content>
<content stylecode="bold"></content>
<content stylecode="bold"> That</content>
<content stylecode="bold"></content>
<content stylecode="bold"> Interfere w</content>
<content stylecode="bold">ith  Hemostasis</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">
<list listtype="unordered" stylecode="disc">
<item>Celecoxib and anticoagulants such as  warfarin have a synergistic effect on bleeding. The concomitant use of Celecoxib and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.</item>
<item>Serotonin release by platelets  plays an important  role in hemostasis. Case-control and cohort epidemiological studies  showed that concomitant use of drugs that interfere  with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.</item>
</list>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor patients  with concomitant use of celecoxib  with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [<content stylecode="italics">see </content>
<content stylecode="italics">
<linkhtml href="#Section_5.11">Warnings and Precautions  (5.11)</linkhtml>
</content>].<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">  Aspirin</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Controlled  clinical studies  showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical  study, the concomitant use of an NSAID and aspirin  was associated  with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [<content stylecode="italics">see <content stylecode="italics">
<linkhtml href="#Section_5.2">Warnings and Precautions (5.2)</linkhtml>
</content>
</content>].<br/>In  two studies in healthy volunteers, and in patients  with osteoarthritis and established heart disease  respectively, celecoxib (200 to 400 mg daily) has demonstrated a lack of interference  with the cardioprotective antiplatelet effect of aspirin (100 to 325 mg).<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of celecoxib and analgesic doses of aspirin is  not generally recommended because of the increased risk of bleeding [<content stylecode="italics">see <content stylecode="italics">
<linkhtml href="#Section_5.11">Warnings and Precautions (5.11)</linkhtml>
</content>
</content>].<br/>Celecoxib is not a substitute for low dose aspirin for cardiovascular protection.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">  ACE</content>
<content stylecode="bold"></content>
<content stylecode="bold"> Inhibitors,</content>
<content stylecode="bold"></content>
<content stylecode="bold"> Angiotensin</content>
<content stylecode="bold"></content>
<content stylecode="bold"> Receptor</content>
<content stylecode="bold"></content>
<content stylecode="bold"> Blockers,</content>
<content stylecode="bold"></content>
<content stylecode="bold"> and</content>
<content stylecode="bold"></content>
<content stylecode="bold"> Beta-Blockers</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">
<list listtype="unordered" stylecode="disc">
<item>NSAIDs may diminish the antihypertensive effect of angiotensin converting  enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).</item>
<item>In patients  who are  elderly, volume-depleted (including those on diuretic therapy), or  have renal impairment, co-administration of an NSAID  with ACE inhibitors or ARBs may result in deterioration of renal function,  including possible acute renal failure. These effects are usually reversible.</item>
</list>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">
<list listtype="unordered" stylecode="disc">
<item>During concomitant use of celecoxib and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.</item>
<item>During concomitant use of celecoxib and ACE-inhibitors or ARBs in patients  who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [<content stylecode="italics">see <content stylecode="italics">
<linkhtml href="#Section_5.6">Warnings and Precautions (5.6)</linkhtml>
</content>
</content>]<content stylecode="italics">.</content>
</item>
<item>When these drugs are administered  concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.</item>
</list>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">  Diuretics</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Clinical studies, as  well as post-marketing observations,  showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin  synthesis.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">During concomitant use of celecoxib  with diuretics, observe patients for signs of  worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [<content stylecode="italics">see </content>
<content stylecode="italics">
<linkhtml href="#Section_5.6">Warnings and Precautions  (5.6)</linkhtml>
</content>].<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">  Digoxin</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">The concomitant use of Celecoxib  with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">During concomitant use of celecoxib and digoxin, monitor serum digoxin levels.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">  Lithium</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">NSAIDs have produced elevations in plasma  lithium levels and reductions in renal lithium clearance<content stylecode="italics">. </content>The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%.  This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">During concomitant use of celecoxib and lithium, monitor patients for signs of  lithium toxicity.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">  Methotrexate</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Concomitant use of NSAIDs and methotrexate may  increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal  dysfunction).<br/>Celecoxib has no effect on  methotrexate pharmacokinetics.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">During concomitant use of celecoxib and methotrexate, monitor patients for methotrexate toxicity.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">  Cyclosporine</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of celecoxib and  cyclosporine may increase cyclosporine’s  nephrotoxicity.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">During concomitant use of celecoxib and  cyclosporine, monitor patients for signs of  worsening renal function.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">  NSAIDs a</content>
<content stylecode="bold">nd  Salicylates</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of Celecoxib  with other NSAIDs or  salicylates (e.g., diflunisal, salsalate) increases the risk of GI  toxicity, with little or no increase in efficacy [<content stylecode="italics">see <content stylecode="italics">
<linkhtml href="#Section_5.2">Warnings and Precautions (5.2)</linkhtml>
</content>
</content>]<content stylecode="italics">.</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">The concomitant use of Celecoxib  with other NSAIDs or  salicylates is not recommended.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> Pemetrexed</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of celecoxib and pemetrexed may increase the risk of pemetrexed-associated  myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">During concomitant use of celecoxib and pemetrexed, in patients  with renal impairment  whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.<br/>NSAIDs  with short elimination half-lives (e.g.,  diclofenac, indomethacin) should be avoided for a period of  two days before, the day of, and  two days  following administration of pemetrexed.<br/>In the absence of data regarding potential interaction  between pemetrexed and NSAIDs  with longer half-lives (e.g., meloxicam, nabumetone), patients taking these  NSAIDs should interrupt dosing for at least five  days before, the day of, and  two days  following pemetrexed administration.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> CYP2C9 Inhibitors or inducers</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Celecoxib metabolism is predominantly mediated via  cytochrome P450 (CYP) 2C9 in the liver. Co­-administration of celecoxib  with drugs that are known to inhibit  CYP2C9 (e.g. fluconazole) may enhance the exposure and toxicity of celecoxib  whereas co-administration  with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of celecoxib.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Evaluate each patient's medical history  when consideration is  given to prescribing celecoxib. A dosage adjustment may be  warranted when celecoxib is administered  with CYP2C9 inhibitors or inducers. [<content stylecode="italics">see <content stylecode="italics">
<linkhtml href="#Section_12.3">Clinical  Pharmacology (12.3)</linkhtml>
</content>
</content>].<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">  CYP2D6</content>
<content stylecode="bold"></content>
<content stylecode="bold"> substrates</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">
<content stylecode="italics">In vitro </content>studies  indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an <content stylecode="italics">in vivo </content>drug interaction  with drugs that are metabolized by  CYP2D6 (e.g. atomoxetine), and celecoxib may enhance the exposure and toxicity of these drugs.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Evaluate each patient's medical history  when consideration is  given to prescribing celecoxib. A dosage adjustment may be  warranted when celecoxib is administered  with CYP2D6 substrates. [<content stylecode="italics">see <content stylecode="italics">
<linkhtml href="#Section_12.3">Clinical  Pharmacology (12.3)</linkhtml>
</content>
</content>].<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">  Corticosteroids</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical  Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of corticosteroids  with celecoxib may increase the risk of GI ulceration or bleeding.<br/>
</td>
</tr>
<tr>
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Monitor patients  with concomitant use of celecoxib  with corticosteroids for signs of bleeding [see <content stylecode="italics">
<linkhtml href="#Section_5.2">Warnings and Precautions (5.2)</linkhtml>
</content>].<br/>
</td>
</tr>
</tbody>
</table>